EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Analisis Cost-Benefit Terapi Simvastatin dengan Atorvastatin pada Pasien Dislipidemia di Apotek 71 Kota Kediri dengan Pendekatan Human Capital Method

Fendy Prasetyawan, Yuneka Saristiana, Ratna Mildawati, Muhammad Nurul Fadel, Emma Jayanti Besan, Widhi Astutik, Chandra Arifin, Abd Rofiq, Eka Hayati Rhomah

Business and Economic Publication · 2025

DOI: 10.32764/bep.v3i2.1571 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Business and Economic Publication, 2025. Verfasst von Fendy Prasetyawan und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to analyze the cost-benefit of simvastatin therapy compared to atorvastatin in dyslipidemia patients at Apotek 71 Kediri City using the Human Capital Method. Using a cross-sectional study design, this study analyzed 60 patients (30 simvastatin users, 30 atorvastatin users). Productivity loss data was collected through a patient self-report questionnaire and valued monetarily using the assumption of a uniform daily wage. Results showed that direct costs of simvastatin were lower (IDR 75,000/month) than atorvastatin (IDR 210,000/month), but lost productivity in the simvastatin group was higher (IDR 384,000) than atorvastatin (IDR 180,000). The Net Benefit value of simvastatin therapy was -Rp 39,000 with a Benefit Cost Ratio (BCR) of 0.91, while atorvastatin produced a Net Benefit of +Rp 210,000 with a BCR of 1.54. The difference in Net Benefit was statistically significant based on an independent t-test (p=0.002). Thus, atorvastatin is more economically efficient than simvastatin because it provides higher productivity benefits despite higher direct costs.

Zitieren

APA

Prasetyawan, F., Saristiana, Y., Mildawati, R., Fadel, M. N., Besan, E. J., Astutik, W., Arifin, C., Rofiq, A., & Rhomah, E. H. (2025). Analisis Cost-Benefit Terapi Simvastatin dengan Atorvastatin pada Pasien Dislipidemia di Apotek 71 Kota Kediri dengan Pendekatan Human Capital Method. Business and Economic Publication. https://doi.org/10.32764/bep.v3i2.1571

Vancouver

Prasetyawan F, Saristiana Y, Mildawati R, Fadel MN, Besan EJ, Astutik W, et al. Analisis Cost-Benefit Terapi Simvastatin dengan Atorvastatin pada Pasien Dislipidemia di Apotek 71 Kota Kediri dengan Pendekatan Human Capital Method. Business and Economic Publication. 2025. doi:10.32764/bep.v3i2.1571

BibTeX
@article{Prasetyawan2025,
  author = {Prasetyawan, Fendy and Saristiana, Yuneka and Mildawati, Ratna and Fadel, Muhammad Nurul and Besan, Emma Jayanti and Astutik, Widhi and Arifin, Chandra and Rofiq, Abd and Rhomah, Eka Hayati},
  title = {Analisis Cost-Benefit Terapi Simvastatin dengan Atorvastatin pada Pasien Dislipidemia di Apotek 71 Kota Kediri dengan Pendekatan Human Capital Method},
  journal = {Business and Economic Publication},
  year = {2025},
  doi = {10.32764/bep.v3i2.1571}
}
Kostenlos starten →